Imperial Clinical Trials Unit

The NIHR Imperial BRC aims to provide patients worldwide with health benefits by delivering excellence in the design, conduct and dissemination of clinical trials of all phases; this is the mission of the Imperial Clinical Trials Unit (ICTU). With expertise in trial methodology and all aspects of delivery in key disease areas, we are able to work on all stages of clinical trials, from generation to delivery. Our trials cover a broad range of disease areas that are highly relevant to global health, including cardiovascular and metabolic disease, oncology, psychological medicine, mental health, respiratory and infectious disease.

ICTU, which is led by Co-Directors Prof Deborah Ashby and Prof Neil Poulter, works across Imperial and Imperial College Healthcare NHS Trust, and with the Royal Brompton and Harefield NHS Foundation Trust and affiliated NHS trusts. We have mixed academic and clinical groups in several therapeutic areas:

Cardiovascular and Metabolic

Led by Prof Neil Poulter, Professor of Preventative Cardiovascular Medicine, the group of five senior cardiovascular academics are working on trials such as ADVANCE-ON and Aardvark.


Led by Prof Charles Coombes, Professor of Medical Oncology & Director of the Imperial CRUK Cancer Centre, and Prof Hani Gabra, Professor of Medical Oncology & Lead Clinician for Cancer Clinical Trials & Head of the Ovarian Cancer Action Research Centre at Imperial College London, this group is running trials including REACT, Radical, I-PET, SLNM and IRIS.


Interim lead Prof John Pepper, Professor of Cardiac Surgery, is overseeing the AZALEA clinical trial.

HIV/Infectious Diseases

Led by Prof Jonathan Weber, Clinical Professor in Communicable Diseases and GU Medicine, this active group is working on trials such as Cuthivac.

Emergency and Critical Care

Led by Dr Anthony Gordon, Professor of Anaesthesia & Critical Care and Consultant in Critical Care Medicine, this group runs trials such as Vanish.

CUTHIVAC Spoke 001

In 2011, an estimated 2.5 million people worldwide were diagnosed with HIV-1. The search for an effective preventative HIV vaccine therefore remains an important global health priority. Different routes of vaccination could affect immune responses; CUTHIVAC 001 is a randomised Phase I study comparing the effectiveness of three HIV GTU® MultiHIV DNA immunisations administered via the intramuscular, intradermal and transcutaneous routes in healthy male and female volunteers.


People who have had a stroke or heart attack need secondary prevention that addresses multiple risk factors; recovery from a stroke or heart attack typically requires multiple medications for cholesterol, blood pressure, and platelet function, which can be complex and costly. UMPIRE assesses whether people in the UK and India prefer taking this medication as several separate tablets or as a single pill – the Red Heart Pill.

Read more about our trials.